UROSCAN (60/76)
(Ionic Contrast Media)
Redifines Clarity and Safety...
High oidine content.
Excellent tolerance.
Rapid excretion.
Least effect on electrolyte balance.
Low toxicity.
Reduced risk of ventricular fibrillation due to presence of Ca2Na2 EDTA stabilizer.
| COMPOSITION | UROSCAN 76 | UROSCAN 60 |
|---|---|---|
| Meglumine Diatrizoate | 66% w/v | 52.1% w/v |
| Sodium Diatrizoate | 10% w/v | 7.9% w/v |
| Iodine Concentration | 370 mg/ml | 292 mg/ml |
| pH | 6.0 to 7.7 | 6.0 to 7.7 |
| Viscosity (mPa*s) | ||
| @37℃ | 8.9 | 4.0 |
| @20℃ | 18.5 | 7.2 |
INDICATIONS:
Urography (IVP/IVU).
Angiocardiography.
Phlebography.
Ventriculography.
Computerised Tomography.
Digital Subtraction Angiography.
Aortography.
Arteriography.
Coronary Angiography / Angioplasty.
Hysterosalpinography (HSG).
Arthrography.
CT Enhancement (Oral use / Rectal use).
CONTRAINDICATIONS:
Manifest hyperthyroidism, de-compensated cardiac insufficiency. Hysterosalpingography must not be performed during pregnancy or in the presence of acute inflammatory processes in the pelvic cavity.
PRESENTATION:
UROSCAN 60 : 20 ml ampoule, 20 ml vial & 50 ml vial.
UROSCAN 76 : 20 ml ampoule, 20 ml vial, 50 ml vial and 100 ml.
STORAGE:
Store at controlled room temperature 20℃ to 30℃.
Do not freeze. Protect from direct sunlight and secondary X-Rays.
Inspect container for particulate matter before use. Discard unused portion.
PLEASE NOTE:
The contrast media solution should not be drawn into the syringe or the infusion bottle until immediately for the examination. Vials containing contrast media solutions are not intended for the withdrawal of multiple doses. The rubber stopper should never be pierced more than once. The use of cannulas with a long tip and a maxium diameter of 18 G is recommended for piercing stopper and drawing up the contrast media. Contrast media not used in one examination session must be discarded.
The need for examination merits particularly careful consideration in hypersensitivity to iodinated contrast media, severe impairment of hepatic or renal function, cardiac and circulatory insufficiency, pulmonary emphysema, poor general halth, cerebral spasmodic condition, latent hyperthyroidism, bland modular goiter and multiple myeloma.
Fluid intake should not be restricted before the use of hypertonic contrast media in patients with multiple myeloma, diabetes mellitus requiring treatment, polyuria, gout and in babies, young children and patients in a very poor state of health. Pre-medication with alpha-receptor blockers is recommended in phaeochromocytoma patients because of the risk of blood pressure.
Following the administration of iodinated contrast media, the capacity of the thyroid tissue to take up radioisotopes for diagnostic disorders of thyroid is reduced for up to two weeks, and even longer in individual cases.
Diabetic nephropathy may predispose to renal impairment following intravascular contrast media administration. this may percipitate acidosis in patients who are taking biguanides.